LLY

795.48

+0.43%↑

JNJ

152.14

-0.14%↓

ABBV

186.94

+0.72%↑

NVO

67.74

+0.61%↑

UNH

302.46

+0.12%↑

LLY

795.48

+0.43%↑

JNJ

152.14

-0.14%↓

ABBV

186.94

+0.72%↑

NVO

67.74

+0.61%↑

UNH

302.46

+0.12%↑

LLY

795.48

+0.43%↑

JNJ

152.14

-0.14%↓

ABBV

186.94

+0.72%↑

NVO

67.74

+0.61%↑

UNH

302.46

+0.12%↑

LLY

795.48

+0.43%↑

JNJ

152.14

-0.14%↓

ABBV

186.94

+0.72%↑

NVO

67.74

+0.61%↑

UNH

302.46

+0.12%↑

LLY

795.48

+0.43%↑

JNJ

152.14

-0.14%↓

ABBV

186.94

+0.72%↑

NVO

67.74

+0.61%↑

UNH

302.46

+0.12%↑

Search

Royalty Pharma PLC (Class A)

Closed

SectorHealthcare

35.25 -1.84

Overview

Share price change

24h

Current

Min

35.01

Max

36.11

Key metrics

By Trading Economics

Income

99M

433M

Sales

-26M

568M

P/E

Sector Avg

14.449

50.291

EPS

1.057

Dividend yield

2.49

Profit margin

76.275

EBITDA

172M

534M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+15.85% upside

Dividends

By Dow Jones

Dividend yield

Sector Avg

2.49%

2.40%

Next Earnings

7 sie 2025

Next Dividend date

12 wrz 2025

Next Ex Dividend date

15 sie 2025

Market Stats

By TradingEconomics

Market Cap

951M

20B

Previous open

37.09

Previous close

35.25

News Sentiment

By Acuity

50%

50%

154 / 380 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Bullish Evidence

Royalty Pharma PLC (Class A) Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

2 cze 2025, 10:49 UTC

Major Market Movers
Acquisitions, Mergers, Takeovers

Theravance Shares Rise Premarket on Sale of Trelegy Royalties

Peer Comparison

Price change

Royalty Pharma PLC (Class A) Forecast

Price Target

By TipRanks

15.85% upside

12 Months Forecast

Average 41.6 USD  15.85%

High 51 USD

Low 33 USD

Based on 5 Wall Street analysts offering 12 month price targets forRoyalty Pharma PLC (Class A) - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

5 ratings

4

Buy

1

Hold

0

Sell

Technical Score

By Trading Central

33 / N/ASupport & Resistance

Short Term

Bullish Evidence

Intermediate Term

Weak Bearish Evidence

Long Term

Bullish Evidence

Sentiment

By Acuity

154 / 380 Ranking in Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Royalty Pharma PLC (Class A)

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 commercial products and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, immunology, respiratory, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.